Abstract:Fibroblast activation protein (FAP) is a serine protease upregulated at sites of tissue remodeling and cancer that represents a promising therapeutic and molecular imaging target. In prostate cancer, studies of FAP expression using tissue microarrays are conflicting, such that its clinical potential is unclear. Furthermore, little is known regarding FAP expression in benign prostatic tissues. Here we demonstrated, using a novel iterative multiplex IHC assay in standard tissue sections, that FAP was nearly absent in normal regions, but was increased consistently in regions of proliferative inflammatory atrophy (PIA). In carcinoma, FAP was expressed in all cases, but was highly heterogeneous. High FAP levels were associated with increased pathological stage and cribriform morphology. We verified that FAP levels in cancer correlated with CD163+ M2 macrophage density. In this first report to quantify FAP protein in benign prostate and primary tumors, using standard large tissue sections, we clarify that FAP is present in all primary prostatic carcinomas, supporting its potential clinical relevance. The finding of high levels of FAP within PIA supports the injury/regeneration model for its pathogenesis and suggests that it harbors a protumorigenic stroma. Yet, high levels of FAP in benign regions could lead to false positive FAP-based molecular imaging results in clinically localized prostate cancer.

What problem does this paper attempt to address?

The paper aims to address the following issues: 1. **Clarify the expression of FAP in benign prostate tissue**: Previous studies have shown conflicting results regarding the expression of fibroblast activation protein (FAP) in prostate cancer, especially in proliferative inflammatory atrophy (PIA) and primary adenocarcinoma. Additionally, little is known about the expression of FAP in benign prostate tissue. 2. **Quantify the expression levels of FAP in different prostate lesions**: By developing a new iterative multiplex immunohistochemistry method, the expression of FAP in standard tissue sections is quantified and its relationship with prostate cancer progression is explored. 3. **Validate the correlation between FAP expression and M2 macrophage density**: Studies have found that FAP levels are associated with the density of CD163+ M2 macrophages, and this relationship is further validated. 4. **Evaluate the potential of FAP as a molecular imaging and therapeutic target**: The study explores whether the high expression of FAP in prostate cancer could lead to false-positive molecular imaging results, thereby affecting clinical applications. Through these studies, the paper aims to clarify the expression patterns of FAP in prostate cancer and its potential clinical significance.

Overexpression of Fibroblast Activation Protein (FAP) in stroma of proliferative inflammatory atrophy (PIA) and primary adenocarcinoma of the prostate